X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - New Drug Approvals - 01/Jul 05:07

FDA Approves Pyzchiva (ustekinumab-ttwe), a Biosimilar to Stelara

Basel, July 1, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved biosimilar Pyzchiva®* (ustekinumab-ttwe) 45 mg/0.5 mL and 90 mg/mL pre-filled...

Articles similaires

Sorry! Image not available at this time

FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara

drugs.com - 30/Sep 21:09

September 30, 2024 -- Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies,...

Sorry! Image not available at this time

FDA Approves Aqneursa (levacetylleucine) for the Treatment of Niemann-Pick Disease Type C

drugs.com - 25/Sep 07:09

AUSTIN, TX, September 25, 2024– IntraBio Inc., a leader in the discovery and development of innovative drugs for rare neurodegenerative...

Sorry! Image not available at this time

UCB announces U.S. FDA approvals for Bimzelx (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

drugs.com - 23/Sep 00:09

Brussels (Belgium), September 23, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, announced today that the U.S. Food and...

Sorry! Image not available at this time

FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

drugs.com - 27/Sep 04:09

PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

drugs.com - 27/Sep 04:09

PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

FDA Approves Miplyffa (arimoclomol) for the Treatment of Niemann-Pick Disease Type C

drugs.com - 20/Sep 05:09

CELEBRATION, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare...

Sorry! Image not available at this time

FDA Approves Flyrcado (flurpiridaz F 18) Radioactive Diagnostic for Enhanced Diagnosis of Coronary Artery Disease

drugs.com - 27/Sep 20:09

ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE) September 27, 2024 --GE HealthCare (Nasdaq: GEHC) today announced that the U.S. Food and Drug Administration...

Sorry! Image not available at this time

FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease

drugs.com - 01/Oct 22:48

TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with...

Sorry! Image not available at this time

FDA Approves First Flu Vaccine That Can Be Self-Administered at Home

drugs.com - 20/Sep 22:09

FRIDAY, Sept. 20, 2024 -- On Friday, the U.S. Food and Drug Administration approved the FluMist nasal vaccine for self-administration at home. It is a...

Sorry! Image not available at this time

FDA Approves, Cobenfy, a New Kind of Drug for Schizophrenia

drugs.com - 27/Sep 10:09

FRIDAY, Sept. 27, 2024 -- The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food...

Les derniers communiqués